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Summary Systemic lupus erythematosus (SLE) patients are characterized by 
a low lymphocyte count, which is considered a specific disease marker  and is re- 
lated to disease activity. The membrane bound molecules CD25 and CD27 are ex- 
pressed and released in a soluble CD25 (sCD25) and soluble CD27 (sCD27) form 
by activation of predominantly T cells. In previous studies it was claimed that 
sCD25 as well sCD27 might be used as parameters for activation of the immune 
system; a correlation between the sCD25 profile with the disease course in SLE pa- 
tients was also shown. 
To assess the relationship between lymphocyte count and these T cell activation 
markers, we performed a cross-sectional nd a longitudinal study. In the longitu- 
dinal study three SLE patients who were known for a long time at our outpatient 
clinic were studied. Both T cell markers strongly correlated with each other and 
formed a reflection of the disease course. In all 7 periods of exacerbation, which 
we observed in the 3 investigated patients, both levels increased preceding this pe- 
riod; however, no correlation was found with the lymphocyte count. In the cross 
sectional study of 69 patients with SLE, sCD25 and sCD27 levels were correlated 
with defined disease manifestations; sCD25 was elevated in all periods of increased 
disease activity. The same holds true for sCD27, with the exception of patients with 
nephritis in which the highest levels were observed. Both profiles of sCD25 and 
sCD27 were strongly correlated uring the whole disease course. Our data prove 
that in the pathogenesis of SLE an active recruitement ofunprimed and primed T 
cells takes place. 
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Disease Activity 
INTRODUCTION 
Quantification of products of T-lymphocyte activation 
could be one method of monitoring disease activity in 
systemic lupus erythematosus (SLE). T-lymphocyte ac- 
tivation requires induction of Interleukin-2 (IL-2) as well 
as its receptor ( IL-2R) (1,2). Activation of T-cells leads 
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to secretion of IL-2 but also a truncated form of its re- 
ceptor, 10 kD smaller than the 55-65 kD membrane bound 
protein, will be released (3,4). The rate of release of this 
molecule (soluble CD25) is in proportion to its cell sur- 
face expression (4,5). Serum levels of soluble CD25 are 
claimed to correlate with disease activity in patients with 
SLE (6). 
Recently another T cell membrane molecule CD27 
was described. Activation of T cells by the T-cell recep- 
tor CD3 (TCR/CD3) complex induces a strong increase 
of CD27 membrane xpression, predominantly on na- 
ive CD45 RA+ cells with a concomittant release of a 28- 
32 kD form of CD27 in the supernatant (soluble CD27) 
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(8-10). Till now the functions of soluble CD25 (sCD25) 
and soluble CD27 (sCD27) are uncertain, but both may 
have an immunoregulatory role. 
Elevated levels of sCD27 have been shown in sarcoi- 
dosis during acute CMV and HIV infections, in synovial 
fluid of rheumatoid arthritis patients and in cerebrospi- 
nal fluid of multiple sclerosis patients (11,21). Further- 
more, evidence is obtained that sCD27 is not released 
by cells lacking CD27 membrane expression. Cells that 
could produce sCD27 were either CD45 RA + or CD45 
RO +, which would indicate that elevated titers of sCD27 
are a reflection of active recruitement of the unprimed 
and primed T-cell pool, rather than an expansion of the 
fully differentiated CD45 RA-CD27- T cells (22). Mea- 
surement of sCD27 in relation to sCD25 might there- 
fore be useful for obtaining insight into the type of cell 
that is activated uring the disease course of patients 
with SLE. 
A remarkable finding in SLE is the occurrence oflym- 
phopenia which is reported in 75% of untreated patients. 
Its presence isclaimed to correlate with disease activity 
(23, 24). The cause of lymphopenia remains unclear, a 
suggestion could be that lymphopenia s more or less a 
reflection of an increased cell turnover. If sCD25 and 
sCD27 are markers for T-cell activation, one might won- 
der if between the degree ofT-cell activation and the ex- 
istence of lymphopenia a relation exists. 
Most studies in SLE patients relating immunological 
parameters (like sCD25) with disease activity, have a 
cross sectional character or are confined to a small num- 
ber of patients followed over a short period of time. Hard- 
ly ever are the investigated parameters studied in the 
same patient with different disease periods character- 
ized by more or less the same disease activity, in order 
to obtain insight into the reproducibility ofthe obtained 
correlations. 
From 1970 all SLE patients known at our institute were 
followed according to fixed protocols to obtain clinical 
data and sera samples. At this moment it was possible 
to make a selection of patients with a disease duration 
of more than a decade. A selection of 3 SLE patients, 
who were known at our institute for such a long time pe- 
riod was made. 
The aim of this study was to evaluate profiles of both 
T-cell activation markers (sCD25 and sCD27) in rela- 
tion to each other and to the disease course in three SLE 
patients. Also in these three extensive longitudinal stud- 
ies the interrelationship between the profiles of sCD25 
and sCD27 was studied in regard to lymphocyte l vels. 
Furthermore, these T-cell activation markers were stud- 
ied in a cross sectional study in 69 SLE patients with de- 
fined clinical symptoms. 
MATERIALS AND METHODS 
Longitudinal study 
From the start of our studies in 1970 clinical data, from 
all patients fulfilling the ARA criteria (19), were record- 
ed using well defined protocols. At that time different 
prospective studies were started to elucidate the diag- 
nostic significance of anti double-stranded DNA (anti- 
dsDNA) (20), and the prognostic significance of anti- 
dsDNA (20, 21). This permitted us now to evaluate pro- 
spectively the disease course of patients who were fol- 
lowed and chosen for this study. Three patients who were 
followed over a long period of time with different dis- 
ease courses and outcomes were analysed. From these 
patients all clinical data for evaluation, and also series 
of regularly sampled sera were available. The different 
disease courses of the patients were divided into peri- 
ods of minor and major disease symptoms as described 
previously (6, 20, 21). This enabled us to compare dif- 
ferent disease periods within the same patient, but also 
with those of the other patients. Minor symptoms are 
mainly restricted to the musculo- skeletal system and the 
skin and may be controlled by an increase of predniso- 
lone dosage of 5 - 15 rag/day without he need for ad- 
mission to hospital. Major symptoms are characterized 
by at least one of the following manifestations: renal im- 
pairment, serositis, anaemia (haemoglobulin < 110 gr/ 
L) and/or leucopenia (white blood cell count < 4 x 10 
9/L) and/or thrombocytopenia (platelet count < 50 x 10 
9/L), neurological or psychiatric symptoms, treated with 
prednisolone dosage of more than 20 mg daily with ad- 
mission to the hospital. All cases in which the symptoms 
were explained by causes other than SLE were exclud- 
ed. 
Patients 
Patient HA, female, born in 1956, developed a symmet- 
rical polyarthritis n 1982. In May 1984 she was admit- 
ted to the hospital with temperature and fatigue. Rou- 
tine laboratory examination revealed aproteinuria ( > 
3.5 gr/L) and positive LE cell preparation confirming the 
diagnosis of SLE. From that ime she was followed at our 
outpatient clinic. A pleuro-pericarditis combined with 
leucocytopenia developed in 1986 in addition to a de- 
crease in renal function to 45 ml/min. (GFR). Treatment 
was started with azathioprine (150 mg/day) and pred- 
nisolone (20 mg/day). She was well till June 1986, when 
she slowly developed periods of temperature and in- 
creasing feeling of fatigue. Admission to the hospital 
took place in November 1987 with a serious kin vascu- 
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litis, and periods of unconciousness. After institution of 
treatment she recovered and the clinical signs subsided. 
In the following years, the disease course was stable un- 
til April 1990 when a further deterioration in renal func- 
tion took place with the same symptoms of periods of un- 
conciousness a in 1988. 
Patient Bo, female, born in 1937, was for the first time 
admitted to the hospital in June 1980 with clinical signs 
of a pleuro-pericarditis and a detoriation of renal func- 
tion. Renal biopsy showed the picture of a diffuse pro- 
liferative glomerulonephritis. Serological examination 
revealed the existence of ANA and the diagnosis of SLE 
was made. She was feeling well till August 1982, when 
she developed pneumonia, which was treated with ampi- 
cilline and for a short time the prednisolone dose was 
increased to 20 rag/day. From that time the disease course 
was stable with only periods of musculoskeletal and skin 
symptoms. In July 1989 she developed alopecia with in- 
creasing complaints of fatigue and temperature. Other 
clinical signs were not found, but to improve her gener- 
al feeling she was treated for a short period with high 
doses of prednisolone (40 mg/day for six weeks). She suf- 
fered mostly of depression. At the end of 1990 nailfold 
lesions developed, signs of her depression worsened, in 
combination with a detoriation of the renal function. In 
September 1990 she was admitted to the hospital with 
the diagnosis of organic-psychosyndrome, nephritis, and 
pleuritis. 
Patient Hey, female, born in 1952, showed in 1982 signs 
of polyarthralgia. Clinical examination revealed a hypo- 
function of the thyroid gland. On serological examina- 
tion anti-nuclear ntibodies were detected. In June 1983 
she developed a period of thrombocytopenia (< 50 x 
10/9) accompanied bya decrease inhaemoglobin with a 
positive Coombs reaction. From that the diagnosis of 
SLE was made and the patient was followed at our out- 
patient clinic. In December 1985, she developed pneu- 
monia and sputum examination showed the existence of 
legionella. She recovered and was well till September 
1989 when at routine xamination it became vident that 
a proteinuria ( < 3.5 gr/day) developed slowly. Renal bi- 
opsy showed the picture of mesangial proliferative glom- 
erulonephritis. Treatment with prednisolone was re- 
fused. In 1990, skin rashes, periods of temperature with 
a further increase in proteinuria, as also a decrease in 
glomerular filtration rate took place. Again at this mo- 
ment she refused treatment with prednisolone but treat- 
ment with azathioprine was instituted. 
Cross sectional study 
From the large group of SLE-patients, known at our lu- 
pus outpatient clinic, 4 groups of patients were select- 
ed. The selection criterion was the availability of a se- 
rum sample during an exacerbation f their disease. 
Group A consisted of 20 SLE-patients with an exacer- 
bation in which they showed signs of active nephritis. Pa- 
tients with pre-established renal involvement were con- 
sidered to be inactive when no significant alteration took 
place in the serum creatinine values, proteinuria, urine 
sediment or blood presure. Renal function was assumed 
to have deteriorated when proteinuria increased at least 
1 gr/24 h and/0r when there was an increase in red blood 
cell count in the urinary sediment or a decrease inglom- 
erular filtration rate (GFR) of more than 20%. Increas- 
es in urinary protein, sediment abnormalities, or decreas- 
es in GFR were considered significant only if observed 
on at least three consecutive days. An increase in pro- 
teinuria or other indications of a further deterioration 
of renal function in the absence of other causes (such as 
pyelonephritis) not being related to SLE were indica- 
tive for renal disease. 
Group B consisted of 12 selected sera of patients who 
during an exacerbation ly showed signs of central ner- 
vous system (CNS) involvement. CNS involvement was 
diagnosed when seizures, coma or changes in mental sta- 
tus in the absence of drugs or other known metabolic 
causes occurred (22). For psychosis, the same criteria 
were used as described earlier (23). 
Group C consisted of 12 SLE-patients who during an ex- 
acerbation only showed signs of a pleuritis and/or peri- 
carditis. Pleuritis was defined as painful in- and experi- 
um with, on auscultation, a pleuritic rub and/or a pleura 
effusion. Pericarditis was defined by typical findings on 
auscultation (pericardial rub), characteristic electrocar- 
diographic abnormalities orby signs of pericardial effu- 
sion observed on X-ray or echocardio-graphic examina- 
tion. 
Group D consisted of 25 SLE patients who during a pe- 
riod showed haematological signs characterised by at 
least one or more of the following manifestations: anaemia 
(Hb < 7 mMol/L) and/or leucopenia (WBC < 4 x 10 
9/L) and/or thrombocytopenia (platelet count < 50 x 10 
9/L). 
Soluble CD27 (sCD27) and CD25 (sCD25) assays 
sCD27 levels were measured as described (10). In brief, 
96-well plates (Maxisorp, Nunc, Denmark) were coated 
with 100 ul of a monoclonal antibody to CD27 (mAb) 
(CLB-CD27/3; 4 ug/ml) in PBS (pH 7.4) per well for two 
hours at 37 ~ C. Non-specific binding sites in the wells 
were blocked by incubation at 37 ~ C with PBS contain- 
ing 1% normal goat serum and 0,1% Tween-20. All fur- 
ther steps were performed using this buffer, unless oth- 
erwise specified. The wells were then washed and filled 
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with 100 ul of sample dilutions in PBS, 0.1% Tween-20, 
10 mMol EDTA and incubated overnight at 4 ~ C. After 
washing, 100 ul of biotinylated mAb CLB-CD27/1 
(lug/ml) was incubated for 1 hour at 37~ After wash- 
ing, a 1:2000 dilution of Avidine-Peroxidase (Sigma)was 
added and incubated for i hour at 37~ After washing, 
100ul of substrate, containing 0.1 mg/ml 3,3', 5,5'-tet- 
ramethylbenzidine (M rck, Darmstadt, FRG) and 0.06% 
hydrogen peroxide dissolved in 0.1 M Sodium Acetate 
buffer (pH 5.5), were added to the wells and after 15' the 
peroxidase reaction was stopped by adding 50 ul of 
2 N H2SO4 and the absorbance at 450 nm was deter- 
mined with a Titertek ELISA reader (Flow Laborato- 
ries, Rockville, MD). The concentrations of sCD27 were 
expressed as units/ml (U/ml), by reference to a standard 
curve that was constructed from absorbance values of se- 
rial dilutions of pooled supernatants of PBMC stimulat- 
ed for 3 days with phytohemagglutinin (lug/ml). The 
amount of sCD27 present in this standard was arbitrari- 
ly set at 100 U/ml. 
sCD25 was quantitated with an ELISA similar to the 
sCD27 assay, but now using MAb 7G7B6 (4ug/ml), that 
was obtained from the ATCC, as coating antibody and 
biotin labeled CLB-CD25/1 (0.5 ug/ml) as conjugate. 
sCD25 units were related to the standard provided with 
a commercially available sCD25 ELISA kit (T Cell Sci- 
ences, Cambridge, MA). The lower detection limits of 
both assays were 50 U/ml. The intra- and interassay vari- 
ation coefficients of the ELISA were 8.4% and 9.4% re- 
spectively (n=42). 
Sera 
Serum was separated from freshly drawn blood and stored 
at -20~ In initial experiments i  was ascertained that re- 
peatedly freezing and/or thawing had no effect on the 
levels of sCD25 and sCD27. The lymphocyte count was 
derived from the total peripheral leucocyte differential 
counts, which was performed in the clinical aboratory 
of the hospital. 
RESULTS 
sCD25 and sCD27 profiles in relation to the disease 
course in three prospectively followed SLE-patients 
In total 7 exacerbations were observed in the investigat- 
ed three patients who were followed over a period of 26 
patient years. Examples of the profiles during periods 
with major symptoms are presented inFigs. 1 and 2. These 
observations are illustrative of all 7 periods, showing an 
increase in the serum levels of both sCD25 and sCD27, 
which dropped when the patient recovered and treat- 
ment was installed. That both profiles of sCD25 and 
sCD27 were comparable was illustrated by plotting them 
against one another (Fig. 3); a strong correlation was 
found between individual serum values. 
During the periods that the patients had a stable dis- 
ease course, the levels remained more or less the same, 
never eaching such levels as observed when the patients 
developed their exacerbations as illustrated inFigs. i and 
2. 
Lymphocyte count in relation to the sCD25 and 
sCD27 profiles in the three disease courses 
Between the different profiles in the three patients ome 
correlations could be observed (Table I). In the period 
preceding an exacerbation the lymphocyte count which 
overall had decreased remained stable; in 3 periods they 
decreased further. In the period of major disease symp- 
toms, the sCD25 and sCD27 levels decreased; in two pe- 
riods a further decrease of the lymphocyte count con- 
comitantly took place, but overall the lymphocyte l vels 
increased as illustrated in Figs. 1 and 2. 
These observations suggest a correlation between the 
lymphocyte count and the levels of sCD25 and sCD27, 
but a statistical significance could not be calculated be- 
tween the absolute values. 
Levels of sCD25 and sCD27 at the moment of major 
symptoms (cross sectional study) 
The results obtained in the cross-sectional study, in which 
the parameters were investigated during the period of 
exacerbation, are shown in Table II and Fig. 4. 
Regarding the sCD25 levels no difference could be cal- 
culated between the different groups of patients. For 
sCD27 clearly significant differences were calculated be- 
tween CNS involvement and nephritis (P < 3.6 10 -4) and 
pleuro-pericarditis (P < 4.9 10 -2) . Overall the highest 
levels were detected inthe nephritis group of sCD25 and 
sCD27. Between the serum levels of sCD25 and sCD27 
and anti-dsDNA no correlation could be demonstrated 
(data not shown). However, all SLE-patients at the mo- 
ment of serum sampling showed increased levels of sCD25 
as well as sCD27 compared with the levels in normals. 
DISCUSSION 
Stimulation of T-cells can be monitored by measuring 
the produced cytokines or by analysis of soluble mem- 
brane antigens that are released by these cells, like sol- 
uble CD25 and CD27. The detection in serum of such 
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Fig. 2: During the disease course (1990) of patient Bo an exacerbation 
developed with mainly symptoms ofan organic psychosyndrome. This 
period was preceded by an increase in the levels of anti-dsDNA, sCD25 
and sCD27. The lymphocyte count was low during the whole disease 
period and increased slightly after the exacerbation a d institution of 
treatment. 
Fig. 1: In the clinical disease course (1987) patient Ha developed an 
exacerbation f her disease. This period was preceded by an increase 
in the anti-dsDNA levels as well of sCD25 and cCD27. Overall a de- 
creased lymphocyte count was observed, which dropped preceding the 
exacerbation a d thereafter increased already before the institution 
of treatment. 
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Fig. 3:sCD25 and sCD27 are plotted against one another, in an attempt to see whether the correlation observed in patient B was also found when 
all individual sera samples were compared. Between both T-cell activation markers a strong correlation could be calculated (p=0.000738). 
Table I: ReNgonship between disease coupe (major disease symptom~ with the lymphocyw count profi~ and TceH acavagon marke~ CD2& sCD2D 
Periods Preceding During/After 
Pat. Lymphoc. * sCD25 sCD27 lymphoc, sCD25 sCD27 
count count 
HA 1985/86 0 ~ ~ $ $ $ 
1987 0 ~ ~ ~ $ $ 
1990 $ ? T ~ 0 $ 
BO 1989 $ $ ~ $ $ $ 
1990 $ $ $ $ $ $ 
HEY 1989 0 ~ ~ $ $ $ 
1990 0 $ ~ $ $ $ 
A* A change in lymphocyte counts was defined as an alteration of more than 20% during the observation period. 
Values were evaluated uring 3 months before (period preceding exacerbation) and thereafter (period during and after exacerbation). 
0=no change; 1" or J, is a change of the separate values as defined. 
Table II: Serum levels of sCD25 and sCD27 at the moment of major dis- 
ease symptoms 
serum levels (units)/ml) 
sCD25 sCD27 
Major symptoms Nos Median( +/-)range Median( +/-)range 
Nephritis 20 982 680 609 302 
CNS involvement 12 862 671 314 164 
Pleurocarditis 12 1044 572 531 275 
Haematological 25 796 601 789 833 
symptoms 
Normal blood bank 20 310 114 186 103 
donors 
Table III: Reported serum levels of soluble CD25 and CD27 in healthy 
controls 
Author 
Hintzen (1991) 
Swaak (1994) 
Wolf (1992) 
Ward (1991) 
Airo (1991) 
Raziuddin (1991) 
Swaak (1994) 
Ref Nos sCD27 (range) 
10 55 105-210 
20 110-390 
sCD25 (mean +/-)  
25 30 197-22 
26 10 235-84 
27 19 301-90 
28 64 212-18 
20 310-114 
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Fig. 4: Serum levels of sCD27 at the moment of defined major disease 
symptoms in systemic lupus erythematosus patients. 
markers for activated T lymphocytes might be useful to 
monitor the disease-course and eventually to evaluate 
the response to therapy in patients with SLE. Our data 
showed that in SLE both soluble T cell markers, sCD25 
and sCD27, are elevated. This was not only the case dur- 
ing an exacerbation, but also when the patients had a 
rather stable disease course. The profiles of sCD25 and 
sCD27 were the same and both levels were strongly cor- 
related with each other. In relation to specific disease 
manifestation, differences were only noted in the levels 
of sCD27. The highest levels were found in patients with 
a nephritis, the lowest levels in patients with CNS in- 
volvement. The profiles of both T cell markers and the 
anti-dsDNA profile showed the same picture. Periods of 
exacerbation were mostly heralded by a low lymphocyte 
count ( < 1.5 x 10 9/1). In a period of 3 months before the 
clinical manifestations of an exacerbation a further de- 
crease took place, in the period of the presence of ma- 
jor symptoms and thereafter the levels increased mostly 
(Table II). Between the lymphocytes count and the sep- 
arate levels of sCD27 ad sCD25 no correlation could be 
calculated. Our results of the levels of sCD25 and sCD27 
are in accordance with those reported in the literature. 
A short survey is given in Table III. Recent studies (6, 
24, 27) have demonstrated that levels of sCD25 are ele- 
vated in SLE. When comparing levels between patients 
with active and inactive disease, significantly higher lev- 
els were described in patients with active disease (24, 28). 
The relation between the anti-dsDNA and sCD25 pro- 
files are conflicting, apositive (6) and negative (26) cor- 
relation is described. Still, overall sCD25 levels were el- 
evated compared with healthy individuals and correlat- 
ed to some extent with the levels of anti-dsDNA. 
Our cross sectional study and the observations in 3 pa- 
tients who were followed over a long time period with 
different periods of major disease manifestations showed 
that sCD25 as well sCD27 levels correlated well with dis- 
ease activity. The strong correlation between both se- 
rum levels of sCD25 and sCD27 sustained that they are 
representative s rological markers for generalized lym- 
phocyte activation. 
Despite the mentioned reports as well as our results 
of the high specificity for disease activity, it should be 
mentioned that various infectious processes can also cause 
elevated sCD25 levels (15, 29). 
In the longitudinal study of three SLE-patients we also 
wanted to investigate the possible relationship between 
the lymphocyte count and the T cell markers and disease- 
activity. At this moment, the mechanism of the low lym- 
phocyte count in SLE is poorly understood and differ- 
ent mechanisms are proposed. Our aim was to find a pos- 
sible correlation between T-cell activation markers and 
the amount of circulating lymphocytes, which might sug- 
gest an increased cell turnover. Between the separate 
levels no correlation could be calculated, but between 
the disease course and the lymphocyte count in most in- 
stances a relationship was shown. 
In conclusion, sCD25 and sCD27 are a reflection of T 
cell activation present in our patients before and during 
an exacerbation. Both levels are increased. Our obser- 
vations also show that in a long time period preceding 
the clinical manifestations of an exacerbation T- cell ac- 
tivation is going on. 
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